-
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
06 Aug 2025 11:25 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “ … risk population. About Arch Biopartners Arch Biopartners Inc. is a …
Director of Communications
Arch Biopartners, Inc.
647-428- … information relating to Arch Biopartners Inc., including our most …
-
On this day: Panthera Biopartners research site opens in York
30 Jul 2025 04:23 GMT
Based at Acomb Garth Community Centre, the site had been operational since May 2024.
It had just had its official launch, conducted by the Lord Mayor of York, councillor Margaret Wells.
The site, operated by primary care provider Nimbuscare, was said to …
-
Arch Biopartners’ Phase II AKI prevention trial begins patient recruitment
23 Jul 2025 13:33 GMT
… through randomised controlled trials.
Arch Biopartners CEO Richard Muruve said: “Congratulations … by the investigator, Arch Biopartners is exploring opportunities to support … the antibiotic imipenem.
Arch Biopartners holds exclusive licensing for method …
-
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
22 Jul 2025 11:30 GMT
… using randomized controlled trials. Arch Biopartners recently manufactured the first-ever … under identifier NCT06886464. About Arch Biopartners Arch Biopartners Inc. is a late … Additional information relating to Arch Biopartners Inc., including our most recent …
-
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22 Apr 2025 10:55 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22 Apr 2025 11:03 GMT
… . Additional information relating to Arch Biopartners Inc., including our most recent …
-
LOUD Ventures and Persephoni BioPartners LLC Announce Strategic Partnership to Transform Therapeutic Innovation
15 Apr 2025 10:00 GMT
… , and operational expertise, and Persephoni BioPartners LLC, a venture studio advancing …
-
Arch Biopartners Closes Non-Brokered Private Placement
14 Mar 2025 20:30 GMT
… 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the … disclosed. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Closes Non-Brokered Private Placement
14 Mar 2025 20:41 GMT
… 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the … disclosed.
About Arch Biopartners
Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Panthera Biopartners Secures £20m In New Clinical Trials
18 Mar 2025 02:21 GMT
business
Image by Konstantin Kolosov from Pixabay
Panthera, the UK’s largest Site Management Organisation (SMO) with a clinical research site in York, has signed two clinical trial contracts worth over £10 million each. These trials, for international …
About
© 1995-2025